Hematological malignancies immunotherapy-related coagulopathy and laboratory tests
10.3760/cma.j.cn114452-20220601-00321
- VernacularTitle:血液肿瘤免疫治疗相关出凝血障碍与实验室检测
- Author:
Yingying LI
1
;
Heng MEI
;
Yu HU
Author Information
1. 华中科技大学同济医学院附属协和医院血液病研究所，湖北省血栓与止血临床医学研究中心，武汉 430022
- Keywords:
Immunotherapy;
Coagulopathy;
Laboratory tests
- From:
Chinese Journal of Laboratory Medicine
2022;45(10):1000-1004
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has been one of the most promising approaches in tumor-treating fields, including immune checkpoint inhibitors, bispecific antibodies, and CAR-T therapy, etc. It has achieved major breakthroughs in the treatment of hematological and other malignancies. However, related safety management issues are becoming increasingly prominent, especially the diagnosis and treatment of coagulopathy deserves the attention of clinical and laboratory physicians. Therefore, this review summarizes immunotherapy-related coagulopathy from the perspectives of epidemiology, pathogenesis and laboratory indicators and provides guidance for early clinical identification, diagnosis and intervention.
